AZAINDOLES USEFUL AS JANUS KINASE INHIBITORS Russian patent published in 2012 - IPC C07D471/04 C07D519/00 A61K31/506 A61K31/517 A61K31/53 A61P25/00 A61P29/00 A61P37/00 

FIELD: chemistry.

SUBSTANCE: invention relates to novel azaindole derivatives, having JAK-2 and JAK-3 kinase inhibiting activity, or pharmaceutically acceptable salts thereof. In formula (I): R³ denotes H; X¹ denotes N or CR⁴; R² denotes H, COOH, COOR' or CONHR'; R⁴ denotes H, F, R, OH, OR', COR', COOH, COOR', CONH₂ or CN; or R² and R⁴, taken together, form a benzene ring optionally substituted with 1-2 R¹⁰; R' denotes C_1-3-alkyl or C_1-3-alkenyl, each optionally substituted 1-2 R⁵; each R⁵ is independently selected from CN, unsubstituted C_1-2alkyl, or two groups R⁵ together with a carbon atom with which they are bonded form a cyclopropyl ring; each R¹⁰ is independently selected from halogen, OCH₃ or OH; R¹ denotes or , R^” is H or denotes C_1-2alkyl, optionally substituted with 1-3 R¹¹; R⁶ denotes C_1-4alkyl, optionally substituted with 1-5 R¹²; values of radicals R⁷ -R⁹, ring A, R¹¹ -R¹⁴. The invention also relates to a pharmaceutical composition containing said compounds and a method of treating or reducing severity of a pathological condition such as allergy, asthma, amyotrophic lateral sclerosis, multiocular sclerosis, graft rejection, rheumatoid arthritis, solid malignant tumour, haematologic malignant disease, leukaemia, lymphoma and myeloproliferative disorders.

EFFECT: high efficiency of using the compounds.

41 cl, 6 ex, 6 tbl